Patents by Inventor Jane E. Shaw

Jane E. Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5286491
    Abstract: A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which will be coextensively coadministered with the sensitizing agent.
    Type: Grant
    Filed: May 18, 1992
    Date of Patent: February 15, 1994
    Assignee: Alza Corporation
    Inventors: Alfred Amkraut, Jane E. Shaw
  • Patent number: 5171576
    Abstract: A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which will be co-extensively coadministered with the sensitizing agent.
    Type: Grant
    Filed: August 30, 1991
    Date of Patent: December 15, 1992
    Assignee: ALZA Corporation
    Inventors: Alfred Amkraut, Jane E. Shaw
  • Patent number: 5077054
    Abstract: A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which will be co-extensively coadministered with the sensitizing agent.
    Type: Grant
    Filed: November 27, 1990
    Date of Patent: December 31, 1991
    Assignee: Alza Corporation
    Inventors: Alfred Amkraut, Jane E. Shaw
  • Patent number: 5000956
    Abstract: A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which wll be co-extensively coadministered with the sensitizing agent.
    Type: Grant
    Filed: July 8, 1988
    Date of Patent: March 19, 1991
    Assignee: Alza Corporation
    Inventors: Alfred Amkraut, Jane E. Shaw
  • Patent number: 4436741
    Abstract: Method and therapeutic system in the form of a bandage that administer scopolamine base transdermally in an initial pulse of 10 to 200 .mu.g/cm.sup.2 of skin that quickly brings the concentration of scopolamine in the plasma to a level at which emesis and nausea are inhibited without intolerable side effects, followed by a substantially constant dosage in the range of 0.3 to 15 .mu.g/hr that holds said level. The bandage is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-scopolamine reservoir lamina that is the source of the constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-scopolamine adhesive layer that is the source of the pulse dose and the means by which the bandage is attached to the skin.
    Type: Grant
    Filed: March 14, 1983
    Date of Patent: March 13, 1984
    Assignee: ALZA Corporation
    Inventors: John Urquhart, Santosh K. Chandrasekaran, Jane E. Shaw
  • Patent number: 3932656
    Abstract: Polymeric materials having at least one exposed surface rendered as a release means for platelet aggregation inhibiting agent by serving as a reservoir for release of aggregation inhibiting prostaglandin. The polymeric surface can also be both platelet aggregation agent releasing and non-thrombogenic agent releasing by having together on the polymeric surface an aggregation inhibiting prostaglandin and an anti-coagulant which are easily released from the surface when in close contact with the blood, plasma or platelets.
    Type: Grant
    Filed: December 20, 1973
    Date of Patent: January 13, 1976
    Assignee: ALZA Corporation
    Inventors: Peter W. Ramwell, Hideo Shio, Jane E. Shaw